1Farinati F,Sergio A,Baldan A,et al.Early and very early hepatocellular carcinoma:when and how much do staging and choice of treatment really matter? A multi-center study[J].BMC Cancer,2009,9:33.
3Holtmann G,Gschossmann J,Karaus M,et al.Randomised double-blind comparison of simethicone with cisapride in functional dyspepsia[J].Aliment Pharmacol Ther,1999,113(1):1459-1465.
4Lecuyer M,Cousin T,Monnot MN,et al.Efficacy of an activated charcoal-simethicone combination in dyspeptic syndrome:results of a randomized prospective study in general practice[J].Gastroenterol Clin Biol,2009,33(6-7):478-484.
5G Holtman,J Gschssmann,P Mayr,et al.A randomized placebo-controlledtrial of simethicone and cisapride for the treatment of patients with functional dyspesia[J].Aliment Pharmacol,Ther2002,16:1641-1648.
5Finney JS, Kinnersley N, Hughes M, et al, Meta-analysis of antisecretory and gastrokinetic compounds in functionaldyspeps[ J ]. J Clin Gastroenterol, 1998, 26(4) :312-320.
6Sakurai-Yamashita Y, Takada K, Takemura K, et al. Ability of mosapride tobind to 5-HT4 receptor in the human stomach [ J ]. Jpn J pharmaeol, 1999, 79 (4) :493-496.
7Talley NJ. Update on the role of drug therapy in non-ulcer dyspepsia [ J ]. Rev Gastroenterol Disord, 2003, 3 ( 1 ) :25-30.
8Hohmann G, Gschossmann J, Mark P, et al. A randomized placebocontrolled trial of simethicone and cisapride for the treatment of patients with functional dyspepsia [ J]. Aliment Pharmacol Ther, 2002,16(9) : 1641-1648.
